Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk

References

• Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and hodgkin’s disease. Brain. 1958 Mar;81(1):93–111.
   PubMed Web of Science ®Google Scholar
• Casado JL, Corral I, Garcia J, et al. Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis. 2014 Feb;33(2):179–187.
   PubMed Web of Science ®Google Scholar
• Steeber DA, Green NE, Sato S, et al. Lyphocyte migration in L-selectin-deficient mice. Altered subset migration and aging of the immune system. J Iimmunol. 1996 Aug 1;157(3):1096–1106.
   PubMed Web of Science ®Google Scholar
• Schneider-Hohendorf T, Philipp K, Husstedt IW, et al. Specific loss of cellular L-selectin on CD4(+) T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection. Aids. 2014 Mar 13;28(5):793–795.
   PubMed Web of Science ®Google Scholar
• Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014 Dec;76(6):802–812.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012 Feb;18(2):143–152.
   PubMed Web of Science ®Google Scholar
• Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013 Sep 3;81(10):865–871.
   PubMed Web of Science ®Google Scholar
• Schwab N, Schneider-Hohendorf T, Pignolet B, et al. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler. 2016 Jul;22(8):1048–1060.
   PubMed Web of Science ®Google Scholar
• Spadaro M, Caldano M, Marnetto F, et al. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. J Neuroinflammation. 2015 Aug 12;12:146.
   PubMed Web of Science ®Google Scholar
• Lieberman LA, Zeng W, Singh C, et al. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology. 2016 Jan 26;86(4):375–381.
   PubMed Web of Science ®Google Scholar
• Voortman MM, Greiner P, Moser D, et al. The effect of disease modifying therapies on CD62L expression in multiple sclerosis. Mult Scler J Exp Transl Clin. 2018 Jul-Sep;4(3):2055217318800810.
   Google Scholar
• Koudriavtseva T, Sbardella E, Trento E, et al. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab. Clin Exp Immunol. 2014 Jun;176(3):320–326.
   PubMed Web of Science ®Google Scholar
• Plavina T, Muralidharan KK, Kuesters G, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. 2017 Oct 10;89(15):1584–1593.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292–302.
   PubMed Web of Science ®Google Scholar
• Boziki M, Lagoudaki R, Melo P, et al. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate. J Neurol Sci. 2019 Jun 15;401:43–50.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulou E, Kosmidis MH, Ioannidis P, et al. Adaptation of addenbrooke’s cognitive examination-revised for the Greek population. Eur J Neurol. 2011 Mar;18(3):442–447.
   PubMed Web of Science ®Google Scholar
• Major EO. History and current concepts in the pathogenesis of PML. Cleve Clin J Med. 2011 Nov;78(Suppl 2):S3–S7.
   PubMedGoogle Scholar
• Gardner SD, MacKenzie EF, Smith C, et al. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol. 1984 May;37(5):578–586.
   PubMed Web of Science ®Google Scholar
• Mengelle C, Kamar N, Mansuy JM, et al. JC virus DNA in the peripheral blood of renal transplant patients: a 1-year prospective follow-up in France. J Med Virol. 2011 Jan;83(1):132–136.
   PubMed Web of Science ®Google Scholar
• Husseiny MI, Anastasi B, Singer J, et al. A comparative study of Merkel cell, BK and JC polyomavirus infections in renal transplant recipients and healthy subjects. J Clin Virol. 2010 Oct;49(2):137–140.
   PubMed Web of Science ®Google Scholar
• Drachenberg CB, Hirsch HH, Papadimitriou JC, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation. 2007 Aug 15;84(3):323–330.
   PubMed Web of Science ®Google Scholar
• Lopez V, Gutierrez C, Burgos D, et al. Prospective study of infection and nephropathy due to BK and JC polyomavirus in 76 kidney transplant recipients. Transplant Proc. 2008 Nov;40(9):2927–2929.
   PubMed Web of Science ®Google Scholar
• Helantera I, Ortiz F, Auvinen E, et al. Polyomavirus BK and JC infections in well matched Finnish kidney transplant recipients. Transpl Int. 2009 Jul;22(7):688–693.
   PubMed Web of Science ®Google Scholar
• Pires EP, Bernardino-Vallinoto CV, Alves DM, et al. Prevalence of infection by JC and BK polyomaviruses in kidney transplant recipients and patients with chronic renal disease. Transpl Infect Dis. 2011 Dec;13(6):633–637.
   PubMed Web of Science ®Google Scholar
• Crowder CD, Gyure KA, Drachenberg CB, et al. Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient. Am J Transplant. 2005 May;5(5):1151–1158.
   PubMed Web of Science ®Google Scholar
• Van Loy T, Thys K, Ryschkewitsch C, et al. JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route. J Virol. 2015 Jan 15;89(2):1340–1347.
   PubMed Web of Science ®Google Scholar
• Wollebo HS, White MK, Gordon J, et al. Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol. 2015 Apr;77(4):560–570.
   PubMed Web of Science ®Google Scholar
• Atwood WJ, Amemiya K, Traub R, et al. Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology. 1992 Oct;190(2):716–723.
   PubMed Web of Science ®Google Scholar
• Monaco MC, Atwood WJ, Gravell M, et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol. 1996 Oct;70(10):7004–7012.
   PubMed Web of Science ®Google Scholar
• Monaco MC, Sabath BF, Durham LC, et al. JC virus multiplication in human hematopoietic progenitor cells requires the NF-1 class D transcription factor. J Virol. 2001 Oct;75(20):9687–9695.
   PubMed Web of Science ®Google Scholar
• Chalkley JJ, Berger JR. Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep. 2013 Dec;13(12):408.
   PubMed Web of Science ®Google Scholar
• Putzki N, Baranwal MK, Tettenborn B, et al. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol. 2010;63(5):311–317.
   PubMed Web of Science ®Google Scholar
• Houff SA, Major EO, Katz DA, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med. 1988 Feb 4;318(5):301–305.
   PubMed Web of Science ®Google Scholar
• Wei G, Liu CK, Atwood WJ. JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J Neurovirol. 2000 Apr;6(2):127–136.
   PubMed Web of Science ®Google Scholar